findmyKOL
Clinical trialNCT01402544TerminatedPhase 2/PHASE3Interventional

Clinical Assessment Of Age-related Macular Degeneration Patients After Early Diagnosis and Treatment With Ranibizumab

SponsorUniversity of California, San DiegoEnrollment20Age-Related Macular Degeneration
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • California Retina Consultants

    Bakersfield, California, United States

  • Shiley Eye Center, Ucsd

    La Jolla, California, United States

  • California Retina Consultants

    Santa Barbara, California, United States

  • Medical Center Ophthalmology Associates

    San Antonio, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
31 Jul 2011
Primary completion
31 Mar 2015
Completion
31 Mar 2015
Last update posted
28 Aug 2019
Registered enrollment
20
Registry id
NCT01402544

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.